Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Return on Sales (2020 - 2025)

Historic Return on Sales for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to 2.1%.

  • ImmunityBio's Return on Sales rose 119500.0% to 2.1% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.22%, marking a year-over-year increase of 759600.0%. This contributed to the annual value of 28.05% for FY2024, which is 9106200.0% up from last year.
  • Latest data reveals that ImmunityBio reported Return on Sales of 2.1% as of Q3 2025, which was up 119500.0% from 3.5% recorded in Q2 2025.
  • ImmunityBio's 5-year Return on Sales high stood at 2.1% for Q3 2025, and its period low was 7357.0% during Q1 2022.
  • Over the past 5 years, ImmunityBio's median Return on Sales value was 579.0% (recorded in 2021), while the average stood at 1314.07%.
  • As far as peak fluctuations go, ImmunityBio's Return on Sales tumbled by -67780000bps in 2022, and later skyrocketed by 70331600bps in 2023.
  • Quarter analysis of 5 years shows ImmunityBio's Return on Sales stood at 234.75% in 2021, then tumbled by -532bps to 1483.92% in 2022, then decreased by -13bps to 1679.24% in 2023, then soared by 100bps to 7.84% in 2024, then skyrocketed by 73bps to 2.1% in 2025.
  • Its last three reported values are 2.1% in Q3 2025, 3.5% for Q2 2025, and 7.85% during Q1 2025.